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Introduction
Following the success of the inaugural Kitasato 
Symposium in 2009 [1], an international faculty of 
researchers and rheumatologists met again at the Palais 
am Festungsgraben, Berlin from the 27 to 29 May 2010 to 
consider the essential role of cytokines in health and their 
contributions to autoimmunity. Approximately 50 scien-
tists from around the world attended the meeting to 
share their experience and expertise in basic research and 
clinical aspects of cytokines and their targeting in the 
treatment of autoimmune disorders (see Table 1 for an 
overview of the main topics).
Keynote lecture
Th  e keynote lecture was delivered by George Kollias 
(Athens, Greece) and considered insights gained from 
animal models on the mechanisms of TNF function in 
chronic inﬂ  ammation and autoimmunity. TNFα plays an 
important physiological role in lymphoid architecture 
and function [2], but is also involved in the pathology of 
chronic inﬂ   ammatory and autoimmune disorders [3]. 
Th   e pleiotropic eﬀ  ects of TNF reﬂ  ect the complexity of a 
system involving both transmembrane and soluble forms 
of TNF and two receptors mediating diﬀ  erent functions 
(Figure 1), as well as eﬀ  ects that depend on the timing 
and localisation of TNF production [4].
Th  is complexity raises the important question of 
whether it may be possible to target the mechanisms by 
which TNF contributes to disease selectively without 
suppres  sing its physiological actions. For example, 
transgenic mice engineered with an uncleavable TNF 
protein are protected against bacterial infection, but 
transmembrane TNF alone is not suﬃ   cient to support 
disease development in the TNF-dependent tristetra-
prolin knockout model of inﬂ   amma  tory arthritis [5]. 
Selective blockade of soluble TNF may therefore be a 
safer alternative to total TNF blockade for the treatment 
of chronic inﬂ  ammation and auto  immunity.
Georg Kollias reviewed studies indicating that patho-
genic TNF/TNF receptor 1 (TNFR1) signalling in inﬂ  am-
matory diseases of both the joints and intestine may be 
mediated speciﬁ   cally by mesenchymal cells such as 
synovial ﬁ   broblasts and intestinal myoﬁ  broblasts. 
Selective mesenchymal expression of the TNFR1 allele 
has been shown to be suﬃ   cient for development of a full 
arthritic and intestinal phenotype in a murine model of 
spondylo  arthritic disease [6]. Th  is may account for the 
commonly observed synovial–gut axis in human disease 
and identiﬁ  es selective targeting of the TNFR1 pathway 
in mesenchymal cells as a promising therapeutic strategy.
Eﬀ   ects of TNF in supporting the development of 
follicular dendritic cells (FDCs) and germinal centres 
may also have important pathological implications. Th  e 
development of autoantibody-mediated spontaneous 
arthritis in the K/BxN murine model has been shown to 
be critically dependent on FDCs. FDC-speciﬁ  c expres-
sion of TNFR1 was necessary and suﬃ   cient to induce 
clustering of FDCs in B-cell follicles and for germinal 
centre formation, and FDC depletion resulting from 
stromal/FDC TNFR1-deﬁ   ciency led to dramatically 
Abstract
The Second Kitasato Symposium: New Prospects 
for Cytokines brought together researchers and 
rheumatologists to consider the essential role 
of cytokines in health and their contributions 
to autoimmunity. Topics addressed during the 
Symposium – which was held in Berlin, Germany 
from 27 to 29 May 2010 – included established and 
new cytokine targets in arthritis and autoimmunity 
and innovative aspects of osteoimmunology as well 
as current perspectives from translational and clinical 
studies. The keynote lecture, delivered by George 
Kollias, focused on insights gained from animal models 
into the mechanisms of TNF function in chronic 
infl  ammation and autoimmunity. The presentations 
at the Symposium resulted in productive discussions 
regarding potential new targets for the treatment of 
rheumatoid arthritis and other autoimmune disorders.
© 2010 BioMed Central Ltd
Kitasato Symposium 2010: New Prospects for 
Cytokines
Gerd R Burmester, Peter E Lipsky and Thomas Dörner*, for the Kitasato Meeting Faculty1
MEETING REPORT
*Correspondence: thomas.doerner@charite.de
CC12, Charite Universitätsmedizin Berlin, Chariteplatz 01, 10098 Berlin, Germany
1Full list of faculy members is available at the end of the article
Burmester et al. Arthritis Research & Therapy 2010, 12:301 
http://arthritis-research.com/content/12/6/301
© 2010 BioMed Central Ltdreduced production of autoreactive antibodies. Further-
more, anti-TNF treatment with etanercept destabilised 
FDC networks leading to reductions in germinal centre 
reactivity, autoantibody production and disease severity 
[7]. Inhibition of the TNF/TNFR1-mediated activities of 
FDCs may therefore contribute to the beneﬁ  cial eﬀ  ects of 
current anti-TNF therapies as well as being a potential 
target for novel treatments.
New targets, new mechanism
Lionel Ivashkiv (New York, USA) considered the regu-
lation of cytokine signalling in inﬂ  ammatory  diseases, 
focusing on the function of the immuno  suppressive and 
anti-inﬂ   ammatory cytokine IL-10. Th  e  homeostatic 
eﬀ  ects of IL-10 are mediated via activation of the Janus 
kinase 1–signal transducer and activator of transcription 
3 (STAT3) signalling pathway, but IL-10 also has the 
IFNγ-like ability to activate macrophages mediated 
through STAT1. In rheumatoid arthritis (RA) the balance 
between activation of STAT3 and STAT1 appears to shift, 
leading to an attenuation of the anti-inﬂ  ammatory func-
tions of IL-10 at the same time as its proinﬂ   am ma tory 
eﬀ  ects are enhanced [8]. TNF may act as an important 
regulator of the cytokine balance by attenuating STAT3 
responses and priming STAT1 res  ponses. Th  is suggests 
that overcoming IL-10 resistance, increasing IL-10 
production, and modulation of IFNs and downstream 
signalling pathways, possibly in combination with anti-
TNF treatment, may be potential therapeutic approaches 
to restoring the cytokine balance in individuals with RA.
Vijay Kuchroo (Harvard, Boston, MA, USA) reviewed 
recent advances in the understanding of the role of Th  17 
cells in the induction and regulation of tissue inﬂ  am-
mation. Th   17 cells have a protective role against certain 
extracellular pathogens but, when dysregulated, can 
induce severe inﬂ  ammation and autoimmunity. Th  ey  are 
eﬀ   ective in providing B-cell help: IL-17 speciﬁ  cally 
Table 1. Overview of cytokines and correlated systems addressed at the second Kitasato meeting 2010.
Cytokine systems and
cytokine/signalling cascades  Specifi  c comments
Soluble and membrane-bound TNF  Distinct roles in autoimmunity versus risk of infection
 Immunomodulatory  eff  ects by TNF blockade on CD4+CD25+ Treg cells
TNFR1 and FDCs  Potential crucial role in autoimmunity
STAT1/3 balance   IL-10 resistance can be modulated by TNF and IFN
IL-17  Counter regulation of Th17 versus Treg cells and emerging role of TH17 cells in providing B-cell help
IL-33   Potential role in resistance to intestinal nematode infection; proinfl  ammatory eff  ects in asthma and arthritis
IL-35   Probably immunosuppressive cytokine with potential to expand Treg cells and suppresses Th17 cells
IL-6/IL-6 receptor/glycoprotein 130  Additional role of this cytokine/signalling system in juvenile arthritis as well as other systemic autoimmune 
  disorders. Role of IL-6/IL-6 receptor in glucose metabolism
Cytokine/chemokine eff  ects on   TNFα, IL-1, IL-17A, IL-6, BAFF/BLyS, APRIL, C-C chemokine receptor 2
osteoblast/osteoclast activity
BAFF/BLyS, APRIL,TNF, IFNα   Role in systemic autoimmunity (that is, systemic lupus erythematosus)
GM-CSF receptor blockade  First trial data in human
Blockade of IL-17A  First trial data in rheumatoid arthritis patients
IL-21  Role in autoimmunity and potential target of therapy
IL-22  Potential to polarise Th17 cells into immunomodulatory IL-22-producing T cells
IL-10  Additional functions of IL-10-producing B cells for immunomodulation
IFNα  Current and new aspects of using IFNα in the treatment of Behçet’s disease
APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor belonging to the TNF family; BLyS, B-lymphocyte stimulator; FDC, follicular dendritic cells; GM-CSF, 
granulocyte/macrophage colony-stimulating factor; STAT, signal transducer and activator of transcription; TNFR1, TNF receptor 1; Treg, T-regulatory.
Figure 1. Pleiotropic functions of TNF and TNF receptor. TACE, 
TNF alpha converting enzyme; tmTNF, transmembrane TNF; TNF, 
tumour necrosis factor; sTNF, soluble TNF; RA, rheumatoid arthritis; 
IBD, infl  ammatory bowel disease; MS, multiple sclerosis; IDDM, insulin-
dependent diabetes mellitus; SLE, systemic lupus erythematosus. 
Figure kindly provided by Dr George Kollias (Athens, Greece).
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Diﬀ  erentiation of Th   17 cells in the mouse is induced by 
transforming growth factor beta together with either IL-6 
or IL-21, followed by self-ampliﬁ  cation involving IL-21 
and then stabilisation by IL-23. Of note, transforming 
growth factor beta in the absence of IL-6 and IL-21 
promotes the generation of T-regulatory (Treg) cells, 
resulting in a reciprocal relationship between Th  17 and 
Treg cells that may present novel targets for treatment of 
inﬂ  ammatory disorders [9].
IL-33 and IL-35 are novel additions to the expanding 
orchestra of cytokines, and Eddy Y Liew (Glasgow, UK) 
considered their functions in health and autoimmunity. 
In mouse models, IL-33 confers resistance to intestinal 
nematode infection and has cardioprotective activity. 
IL-33 has been shown, however, to exacerbate asthma, 
collagen-induced arthritis and Th  eiler’s virus-induced 
encephalitis, and to induce allergic anaphylaxis, as well as 
being associated with Alzheimer’s disease. In a recent 
study, IL-33 was shown to attenuate sepsis by preventing 
the downregulation of CXCR2 expression and chemo-
taxis, so enhancing neutrophil inﬂ  ux into the infection 
site [10]. IL-35 is an immunosuppressive cytokine that 
expands Treg cells, suppresses Th   17 cell development and 
enhances Th  1  diﬀ   erentiation. Protection against 
collagen-induced arthritis in mice suggests a possible role 
for IL-35 in the treatment of inﬂ  ammatory diseases [11].
Costantino Pitzalis (London, UK) asked whether 
synovial pathobiology can be used to predict the clinical 
phenotype and response to treatment in patients with 
arthritis. RA is a highly heterogeneous condition with a 
variable clinical course resulting in major diﬀ  erences in 
joint damage and disability. Th  e Pathobiology of Early 
Arthritis Cohort is a multicentre collaboration with the 
aim of identifying and characterising early biomarkers of 
disease development and progression using minimally 
invasive, ultrasound-guided synovial biopsy. Information 
gained will assist with tailoring treatment to achieve 
optimal outcomes for each patient [12].
Established cytokines and new perspectives
Norihiro Nishimoto (Osaka, Japan) – one of the pioneers 
in discovering the role of the IL-6/IL-6 receptor (IL-6R) 
system – reviewed the results of studies of IL-6 blockade 
using the humanised anti-IL-6R monoclonal antibody, 
tocilizumab, in a variety of disorders. Tocilizumab can 
alleviate many of the manifestations of multicentric 
Castleman’s disease, including chronic inﬂ  ammatory 
symptoms, skin rash, wasting, interstitial pneumonia and 
secondary amyloidosis [13]. Tocilizumab has also been 
shown to reduce disease activity in both RA [14] and 
systemic lupus erythematosus (SLE) [15].
IL-6 signals are transmitted via glycoprotein 130, 
classically as a result of IL-6 binding to the 
membrane-bound IL-6R. However, IL-6 can also activate 
glyco  protein 130 through binding to a soluble form of the 
IL-6R, a phenomenon termed IL-6 trans-signalling. Stefan 
Rose-John (Kiel, Germany) presented evidence that 
ADAM17, the disintegrin metalloproteinase respon  sible 
for membrane shedding of the IL-6R, may act as a 
molecular switch between the proinﬂ  ammatory and anti-
inﬂ  ammatory activities of IL-6 by aﬀ  ecting the balance of 
signalling between the membrane-bound and soluble 
forms of the IL-6R. Given that IL-6 trans-signalling 
appears to be the predominant mode of IL-6 signalling in 
inﬂ   ammatory arthritis [16], Professor Rose-John con-
cluded that selective inhibition of IL-6 trans-signalling 
(for example, with recombinant variants of soluble glyco-
protein 130) may have advantages over global IL-6 blockade.
Jens Brüning (Cologne, Germany) then considered the 
role of IL-6 in metabolism and obesity-associated insulin 
resistance. In the acute physiological setting, the actions 
of IL-6 are antidiabetic, promoting glucose metabolism 
and muscle glucose uptake in a manner similar to insulin 
[17]. IL-6 expression in hepatocytes is promoted by 
neuronal insulin action, and hepatic IL-6 signalling may 
be important for glucose homeostasis. Knockout mice 
lacking hepatocyte IL-6Rs exhibit skeletal muscle insulin 
resistance but hepatic glucose production is unaltered. 
TNF neutralisation or Kupﬀ  er cell ablation can restore 
glucose sensitivity in the knockout mice, suggesting that 
IL-6 signalling in hepatocytes may promote glucose dis-
posal by skeletal muscle by limiting Kupﬀ  er cell activation 
and the development of systemic inﬂ  ammation.
Andrew Cope (London, UK) reviewed the multifaceted 
immunomodulatory activities of TNF and the eﬀ  ects of 
TNF blockade. In particular, TNF was found to inhibit 
the suppressive activity of CD4+CD25+ Treg cells, and anti-
TNF therapy has been shown to restore the deﬁ  cit of Treg 
suppressive function in patients with RA [18]. Recent 
studies have also shown that CD4+ T cells from patients 
with RA are defective in the CD3/CD46-induced IFNγ/
IL-10 switch in which Treg 1 cells are derived from Th  1 
precursors, and that this switch is restored by TNF 
blockade.
Osteoimmunology
Th   e next session considered the role of cytokines in bone 
metabolism and arthritis, which has also been recognised 
by the collaborative research initiative Immunobone 
from the German Research Council DFG. Recent 
evidence from animal models indicates that, despite the 
success of anti-TNF therapy in controlling the signs and 
symptoms of arth  ritis, these drugs do not appear to aﬀ  ect 
the structural changes of ankylosing spondylitis. A new 
hypothesis for the relationship between inﬂ  ammation 
and ankylosis was presented by Rik Lories (Leuven, 
Belgium), in which the two processes are largely 
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entheseal stress (probably involving biomechanical stress 
and microdamage; Figure 2) [19]. Lories identiﬁ  ed bone 
morphogenetic protein and Wnt signalling pathways as 
potential targets for treat  ment to prevent or delay 
ankylosis.
Kurt Redlich (Vienna, Austria) discussed chemokine 
control of bone metabolism based on studies of C-C 
chemokine receptor 2 knockout mice. CCR2–/– mice have 
increased bone mass and strength because of a reduction 
in the number, size and function of osteoclasts, and are 
protected from osteoporosis [20]. Th  e results indicate a 
new pathway in the regulation of bone homeostasis in 
which binding of chemokines to C-C chemokine receptor 
2 induces signalling via NFκB and extracellular signal-
regulated kinase 1/2, leading to increased receptor 
activator of NFκB (RANK) expression by osteoclast 
progenitor cells, making them more susceptible to RANK 
ligand-induced osteoclastogenesis. Cytokine regulation 
of osteoclastogenesis was considered further by Jochen 
Zwerina (Erlangen, Germany), with speciﬁ  c reference to 
TNF, IL-1, IL-17 and IL-6. IL-1 is an essential mediator of 
TNF-induced osteoclastogenesis while IL-17A blockade 
has been shown to reduce the production of TNF-
induced synovial osteoclasts, although this did not result 
in improvements in disease severity in the hTNFtg 
murine model of RA. Recently, IL-6 blockade was shown 
to potently inhibit osteoclast formation and bone erosion 
in hTNFtg mice without suppressing joint inﬂ  ammation, 
suggesting that IL-6 blockade may have beneﬁ  cial eﬀ  ects 
on bone structure in the treatment for arthritis [21].
Michael Cancro (Philadelphia, PA, USA) closed with a 
presentation on plasma cell–osteoclast cross-talk and the 
role of the BLyS/BAFF family of ligands and receptors in 
the development and maintenance of antigen-experi  enced 
pools. Bidirectional cross-talk between emerging RANK-
ligand expressing plasma cells and APRIL-producing 
stromal elements underlies the ability of some antigen-
experienced cells, such as long-lived plasma cells, to drive 
their own niche formation and mainten  ance. Changes in 
B-cell sensitivity to and reliance on BLyS/BAFF family 
ligands contribute to germinal centre competition and 
selection, through interactions between germinal centre B 
cells and BLyS/TACI-expressing TFH cells [22].
Cytokines and systemic autoimmunity: pros and 
cons in systemic lupus erythematosus
Fritz Melchers (Berlin, Germany) began by noting that 
approximately one-half of all B cells are located in gut-
associated lymphoid tissues, and that very little is known 
about these cells. Consequently, intestinal bacteria may 
be important in determining the response to anti-CD20 
therapies (for example, rituximab) and, at least in part, 
account for the variable outcomes seen in clinical 
practice. Xavier Mariette (Paris, France) went on to 
consider the role of cytokines acting on B cells under 
autoimmune conditions. Early RA is associated with 
activation of B cells apparently driven by IL-6 but not 
BLyS/BAFF. In contrast, BLyS/BAFF does appear to play 
a role in B-cell activation in Sjögren’s syndrome and, in 
cooperation with IL-17, in SLE [23]. Interestingly, BLyS/
BAFF can be secreted by diﬀ  erent types of cells, and in 
particular epithelial cells, after IFNα stimulation (23bis) 
and virus infection of these cells. Th  is can explain why 
BLyS/BAFF is involved in Sjögren’s syndrome and in SLE, 
two diseases associated with an IFN signature (23ter). 
Exacerbation of IFNα and BLyS/BAFF overexpression 
may account for the lack of eﬃ   cacy of TNF blockade 
(etanercept) as treatment for Sjögren’s syndrome [24].
SLE is associated with the production of short-lived 
plasmablasts with a deﬁ   nite IFNα signature. Recent 
studies reviewed by Falk Hiepe (Berlin, Germany) have 
identiﬁ   ed a speciﬁ   c plasmablast subset that expresses 
HLA-DR very strongly, and have shown that this HLA-
DRhigh cell fraction (but not the HLA-DRlow  fraction) 
correlates closely with SLE disease activity and anti-DNA 
autoantibody titre [25]. Th  is suggests that plasmablasts 
may make a distinct contribution to the pathogenesis of 
SLE, and may also be susceptible to immunosuppressive 
therapy where more diﬀ   erentiated, long-living plasma 
cells are resistant.
Martin Schiller (Heidelberg, Germany) considered the 
evidence that accumulation of apoptotic cell-derived 
membrane microparticles as a result of increased 
Figure 2. The entheseal stress hypothesis for the relationship 
between infl  ammation and ankylosis in spondyloarthritis. 
BMP, bone morphogenetic protein; DISH, diff  use idiopathic 
skeletal hyperostosis; FOP, fi  brodysplasia ossifi  cans progressiva; 
IBD, infl  ammatory bowel disease; ERAP, endoplasmic reticulum 
aminopeptidase. Reproduced with permission from Lories RJ, Luyten 
FP, de Vlam K: Progress in spondylarthritis. Mechanisms of new bone 
formation in spondyloarthritis. Arthritis Res Ther 2009, 11:221 [19].
The “Leuven” or entheseal stress hypothesis
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the auto  immune response in SLE. Th  ese microparticles 
repre  sent a source of nuclear autoantigens and have been 
shown to induce the maturation of dendritic cells. 
Further, they stimulated plasmacytoid dendritic cells to 
produce IFNα.
Martin Aringer (Dresden, Germany) reviewed the role 
of cytokines other than IFNα in SLE. For example, IFNγ 
signalling via STAT1 is activated in peripheral blood 
mono  nuclear cells from patients with SLE [26], and 
serum levels of TNF and IL-18 have been shown to 
correlate with SLE disease activity. TNF blockade 
(inﬂ  iximab) is associated with clinical improvements in 
patients with SLE, including a marked reduction in 
proteinuria, but is also associated with autoantibody 
production in a majority of patients [27]. TNF blockade 
was also shown to reduce IL-18 levels, suggesting that 
TNF to some degree drives IL-18 changes in SLE.
Clinical aspects of cytokine interventions
Asking whether additional cytokine-targeted therapies 
are actually needed, Kurt Redlich (Vienna, Austria) 
identiﬁ  ed the goals of therapy in RA as alleviating the 
signs and symptoms of inﬂ  ammation, halting and ideally 
reversing joint destruction, and restoring normal physical 
function and quality-of-life. Given that treatment should 
aim for remission, and that this is rarely achieved with 
current treatment options, Redlich concluded that new 
biological therapies are indeed needed [28].
Gerd-Rüdiger Burmester (Berlin, Germany) considered 
the clinical value of blocking signalling via the granulocyte/
macrophage colony-stimulating factor (GM-CSF) path-
way. GM-CSF is elevated in synovial ﬂ  uid from patients 
with RA, and targeting the GM-CSF pathway in animal 
models of RA reduced disease activity. Recently, the 
results from the ﬁ  rst study in humans of a monoclonal 
antibody (CAM-3001) targeting the GM-CSF pathway 
were reported [29]. CAM-3001 had an acceptable safety 
proﬁ   le in the phase I study and presented nonlinear 
pharmacokinetics, presumably because of an antigen-
sink eﬀ  ect, with a half-life of 11 to 21 days. Although the 
study was not designed to assess eﬃ   cacy, improvements 
in disease activity, reductions in C-reactive protein and 
normali  sation of the erythrocyte sedimentation rate were 
seen with CAM-3001 and suggest potential clinical 
beneﬁ  ts of GM-CSF blockade in the treatment of RA.
Hendrik Schulze-Koops (Munich, Germany) presented 
recent data showing increased IL-17 levels and Th  17  cell 
frequencies in the peripheral circulation of patients with 
very early psoriatic arthritis or RA, but not osteoarthritis. 
Inﬂ   ammatory arthritis is associated with increased 
expression of Th  17 cells that are resistant to the 
inhibitory eﬀ  ects of IL-4 and IFNγ, an observation that 
correlates with disease activity.
Epigenetics describes all heritable and potentially 
rever  sible changes in genome function not involving 
altera  tions in the DNA nucleotide sequence, and includes 
mechanisms such as acetylation, ubiquitylation, methy-
lation, phosphorylation and inhibitory RNA (microRNA). 
Steﬀ  en Gay (Zurich, Switzerland) considered the poten-
tial role of epigenetic modulation of gene expression in 
the development of RA. For example, the balance of 
histone acetyl-transferase/histone deacetylase activity is 
strongly shifted towards histone hyperacetylation in 
synovial tissue from patients with RA, and this may lead 
to the activation of proinﬂ  ammatory transcription factors 
[30]. Recent studies have shown that RA is associated 
with altered microRNA expression, including enhanced 
expression of microRNA-155, which suppresses levels of 
matrix metalloproteinase-3, suggesting that microRNAs 
may be involved in modulating bone destruction by 
synovial ﬁ  broblasts [31]. Research has also shown that 
the aggressive RA synovial ﬂ  uid is hypomethylated [32].
Recent translations of cytokine insights from the 
bench
Warren Leonard (Bethesda, MD, USA) reviewed the 
evidence that IL-21 is critical to the development of 
certain autoimmune diseases, including type I diabetes 
and SLE, but may also have therapeutic utility for cancer 
treatment [33]. IL-21 induces the expression of the 
Prdm1  gene by B  cells and T cells, which encodes 
B-lymphocyte-induced maturation protein 1, a critical 
regulator of plasma cell diﬀ   erentiation. Most IL-21-
regulated genes, including Prdm1, are associated with 
combined STAT3– interferon regulatory factor 4 (IRF4) 
promoter sites, and IL-21-induced STAT3 binding is 
dramatically reduced in the absence of IRF4 [34]. Th  is 
suggests an important role for IRF4 alongside STAT3 in 
the regulation of TFH diﬀ   erentiation, which was con-
ﬁ  rmed.  Th  ese ﬁ   ndings furthermore suggest that other 
cytokines and biological processes that depend on STAT3 
may also utilise IRF4.
IL-22 is a member of the IL-10 family that promotes 
innate immunity, with overexpression associated with 
dermatitis and psoriasis. Carlo Chizzolini (Geneva, 
Switzerland) presented data showing that the production 
of IL-22 by human Th    cells can occur either alongside or 
independently of IL-17 and/or IFNγ. Th  e emergence of 
IL-17-producing and IL-22-producing T cells is diﬀ  er  en-
tially regulated, with ligands of the aryl hydrocarbon 
receptor favouring IL-22 expression and with prosta-
glandin E2 acting synergistically with IL-23 to favour 
IL-17 expression [35]. Th   e results suggest that signalling 
through the aryl hydrocarbon receptor may be important 
in shifting the polarisation of T cells from an IL-17-
producing pheno  type to an IL-22-producing phenotype, 
with possible clinical consequences in terms of impaired 
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[36,37].
Th   e potential for B-cell-based therapy in autoimmune 
disorders was considered by Simon Fillatreau (Berlin, 
Germany), who asked whether it might be possible to 
design an ideal therapeutic B cell combining the weak 
immunogenicity of resting B cells with the eﬀ  ective 
suppressive functions of activated B cells. Fillatreau 
reviewed studies showing that quiescent B cells can be 
reprogrammed to present antigen and secrete IL-10, and 
that transfer of these reprogrammed B cells protects 
against experimental autoimmune encephalomyelitis in 
mice by suppressing adaptive immunity and preventing 
immune-mediated tissue degradation.
Ina Kötter (Tübingen, Germany) summarised the 
results of studies investigating IFNα as a treatment for 
Behçet’s disease, which is an inﬂ  ammatory  disorder 
associated with wide-ranging symptoms including mouth 
and genital ulcers as well as eye inﬂ  ammation. A meta-
analysis of trials conducted in 2004 indicated that IFNα2a 
is an eﬀ  ective alternative for the treatment of Behçet’s 
disease, particularly with regards to mucocutaneous 
lesions [38], and subsequent studies have demonstrated 
consistent beneﬁ  ts [39]. In a recent study, all except one of 
53 patients (98%) with severe uveitis caused by Behçet’s 
disease responded to IFNα2a treatment, with treatment 
discontinued in remission for 89% of the patients. Fifty per 
cent of patients were still in remission nearly 4 years after 
cessation of a ﬁ  rst course of IFNα2a treatment [40]. IFNα2a 
was shown to normalise pathologically elevated numbers 
of γδT cells, as well as decreased intracellular levels of IL-
2. Serum IFNα levels were already increased in the patients 
before treatment, however, as were B-cell numbers, and 
both increased further under therapy. Th   e mechanism of 
action of IFNα in Behçet’s disease hence remains to be 
clariﬁ  ed, as some of its eﬀ  ects at ﬁ  rst sight appear to be 
more immunostimulatory than immunosuppressive.
Conclusions
Th   e Second Kitasato  Symposium brought together 
experts in both basic and clinical research to discuss the 
physiological roles of cytokines as well as their contribu-
tions to inﬂ  ammatory and autoimmune disorders. Th  e 
lively discussions highlighted the rapid and substantial 
advances in our understanding of the interplay of 
inﬂ   ammatory pathways and elements of the immune 
system in RA and other disorders. With the insights 
gained, it may be possible to develop new treatment 
strategies and interventions with the aim of improving 
outcomes for the many people aﬀ  ected by autoimmune 
disorders.
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